For Millions of Americans Enduring Chronic Pain, Support Is Overdue

Making progress with SUPPORT

When Congress passed the SUPPORT Act in 2018, it took important steps toward improving the treatment of pain, as well as addressing the opioid epidemic.

Using a public health — rather than a punitive — approach, the act sets prescribing guidelines to reduce reliance on prescription opioids and requires the U.S. Food and Drug Administration (FDA) to develop opioid prescribing guidelines for acute pain. The act also supports research and development of nonopioid alternatives to treating pain and public education about opioid risks and alternatives.

Despite important progress, the act hasn't been fully implemented by relevant agencies, including the FDA and the National Institutes of Health (NIH).

"We appreciate the magnitude of the tasks facing the agencies, but given the long-term importance of the needs for better pain treatments, we continue to urge the FDA and NIH to appropriately prioritize work in this area," said HealthyWomen CEO Beth Battaglino, RN-C. "We believe that there is an absolute need to develop and make multiple treatment modalities available, including nonaddictive and nonpharmacological interventions for chronic pain."

Federal agencies must pick up the pace on implementing the act's key components, including encouraging public dialogue, conducting research, setting treatment guidelines and developing individualized treatment approaches:

Encouraging public dialogue

"The act has further enabled conversations not only within the agencies but in Congress as well on the important focus on treatment of pain and how to prevent opioid use disorder and the misuse of opioid medicines. This must be done while also recognizing that opioids may be appropriate for certain patients when alternatives are inappropriate or contraindicated," Battaglino said.

These conversations must continue — and accelerate.

Battaglino urges federal agencies to gather more public input at local and regional levels to guide its actions.

"Patient perspectives are often unique and unknown to regulators," she said. Gathering this information will help the FDA and NIH design research requirements that can offer clarity and predictability on treatment options for patients and providers.

Conducting research

Despite extensive pain research, there are still many unknowns about underlying pain mechanisms and population differences. The FDA and the NIH should consider how genetic, sex and age differences affect people's experience of pain and what treatments may bring relief.

Setting treatment guidelines

Clinical guidelines and education for healthcare providers are also essential.

"Physicians get very little education on pain in medical school and feel ill-equipped to manage pain problems that are often complex without easy answers," Steinberg said. "They have gotten a strong message not to prescribe opioids and often don't know what else to do."

Ideally, healthcare providers would use an integrative, collaborative approach with patients, according to Quinlan-Colwell. Unfortunately, patients, especially vulnerable ones, rarely get that level of care, she added.

Evidence-based guidelines will help providers care for patients with pain and ensure that patients get the standard of care they deserve.

Guidelines for treating acute pain may also help prevent future problems. "The absolute best way to prevent acute [pain] from becoming chronic pain is to well manage acute pain using a multimodal approach," said Quinlan-Colwell.

Developing Individualized treatment approaches

According to Penney Cowan, founder and CEO of the American Chronic Pain Association and a HealthyWomen Chronic Pain Advisory Board member, the act addresses the needs of many underserved and underrepresented populations and takes into account behavioral health needs. "That tells me [the authors of the act] are looking toward a more balanced approach to pain management."

But fully implementing the act — which will require congressional oversight to hold agencies accountable — is critical to ensuring the development of new, individualized approaches for treating pain, particularly nonopioid medicines.

"There's no magic bullet," Steinberg said. "Everybody is an individual, and people have to combine a number of different modalities to manage their pain."

Developing new approaches — and covering a wide range of treatment options — has the potential to help people living with pain while preventing and treating opioid use disorder.

Patients’ voices matter

To spur the agencies to action, patients living with pain should become advocates.

"Nothing really happens unless advocates speak out for change," Steinberg said.

She encourages people to speak up about inadequate treatment they receive. She suggests calling or emailing members of Congress or state representatives to demand better care.

"One person can make a difference," she said. "If people were more vocal about these real facts regarding pain, I think pain care would improve."

Concretely, chronic pain patients and their allies can advocate for the pain provisions in the SUPPORT Act to be implemented. The act has the potential to improve our understanding of pain through basic research, standardize treatment guidelines and expand treatment options. These changes could bring relief to millions of Americans living in pain — but only if implementing the act becomes a priority.

This resource was created with support from Pfizer.